Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2009-05-11
2010-11-09
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S139100, C424S141100, C514S885000
Reexamination Certificate
active
07829093
ABSTRACT:
Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.
REFERENCES:
patent: 4762914 (1988-08-01), Auron et al.
patent: 4766069 (1988-08-01), Auron et al.
patent: 4772685 (1988-09-01), Schmidt et al.
patent: 4935343 (1990-06-01), Allison et al.
patent: 5001057 (1991-03-01), Auron et al.
patent: 5077219 (1991-12-01), Auron et al.
patent: 5122459 (1992-06-01), Conlon et al.
patent: 5286847 (1994-02-01), Gehrke et al.
patent: 5348858 (1994-09-01), Uetsuki et al.
patent: 5474899 (1995-12-01), Lisi
patent: 5484887 (1996-01-01), Kronheim et al.
patent: 5510462 (1996-04-01), Auron et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681933 (1997-10-01), Auron et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5789185 (1998-08-01), Lisi
patent: 5869619 (1999-02-01), Studnicka
patent: 5885793 (1999-03-01), Griffiths
patent: 5959085 (1999-09-01), Garrone et al.
patent: 6899878 (2005-05-01), Graham et al.
patent: 7531166 (2009-05-01), Masat et al.
patent: 2003/0022869 (2003-01-01), Wiemer et al.
patent: 2003/0026806 (2003-02-01), Witte et al.
patent: 2003/0124617 (2003-07-01), Gram et al.
patent: 2003/0166069 (2003-09-01), Welcher et al.
patent: 2004/0023869 (2004-02-01), Sims et al.
patent: 2004/0063913 (2004-04-01), Gram et al.
patent: 2005/0084493 (2005-04-01), Witte
patent: 2005/0152850 (2005-07-01), Engebretson
patent: 2005/0186615 (2005-08-01), Lin et al.
patent: 2005/0256197 (2005-11-01), Engebretson
patent: 2006/0094663 (2006-05-01), Chemtob
patent: 2009/0060918 (2009-03-01), Masat et al.
patent: 2009/0060923 (2009-03-01), Masat et al.
patent: 0267611 (1993-05-01), None
patent: 0161 901 (1993-12-01), None
patent: 0364778 (1996-03-01), None
patent: 0569687 (2002-08-01), None
patent: 95/01997 (1995-01-01), None
patent: 0216436 (2002-02-01), None
patent: 0216436 (2002-02-01), None
patent: 03/010282 (2003-02-01), None
patent: 03/034984 (2003-05-01), None
patent: 03/073982 (2003-09-01), None
patent: 2004002512 (2004-01-01), None
patent: 2004022718 (2004-03-01), None
patent: 2004/067568 (2004-08-01), None
patent: 2004/072116 (2004-08-01), None
patent: 2005019259 (2005-03-01), None
patent: 2005084696 (2005-09-01), None
patent: 2006/081139 (2006-08-01), None
patent: 2007002261 (2007-01-01), None
Beers and Berkow (1999) The Merck Manual of Diagnosis and Therapy, 17thedition, pp. 169-177.
U.S. Appl. No. 12/463,741, filed May 11, 2009, Masat, et al.
U.S. Appl. No. 12/463,844, filed May 11, 2009, Masat, et al.
U.S. Appl. No. 12/464,006, filed May 11, 2009, Masat, et al.
U.S. Appl. No. 12/464,061, filed May 11, 2009, Masat, et al.
Abbott RD, Gout and coronary heart disease: the Framingham Study, J Clin Epidemiol. 41:237-242 (1988).
Abramson et al., Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 41 :972-980 (2002).
Akahoshi, et al., Recent advances in crystal-induced acute inflammation, Current Opinion in Rheumatology 19:146-150 (2007).
Alheim, et al., Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1 beta, and altered brain cytokine mRNA and serum cytokine levels in IL 1 beta deficient mice. Proc. Natl. Acad. Sci. 94:2681-686 (1997.
Arend et al., Binding of IL-1a, IL-113, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J. Immunol. 153:4766-4774 (1994).
Arend, The balance between IL-1 and IL-1Ra in disease, Cytokine & Growth Factor Reviews 13:323-340 (2002).
Arnett FC, Edworthy SM, Bloch, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31:315-324 (1988).
Barzilay, et al., Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354:622-25 (1999).
Bieber and Terkeltaub, On the Brink of Novel Therapeutic Options for an Ancient Disease, Arthritis & Rheumatism 50 (8):2400-2414 (2004).
Bloomgarden, Concepts of Insulin Resistence, Metabolic Syndrome and Related Disorders, 3(4):284-293 (2005).
Boraschi et al., A monoclonal antibody to the IL-1 beta peptide 163-171 blocks adjuvanticity but not pyrogenicity of IL-1 beta in vivo. J. Immunol 143:131-134 (1989); Erratum in: J. Immunol. 143:1403 (1989).
Boraschi et al., Differential inhibition of IL-113 activities and receptor binding of monoclonal antibodies mapping within a discrete region of the protein. Lymphokine Cytokine Res 10:377-384 (1991).
Braddock and Quinn, Targeting IL-1 in Inflammatory Disease: New Opportunities for Therapeutic Intervention, Nature Reviews-Drug Discovery 3:1-10 (2004).
Brand, et al., Activation and Translocation of p38 Mitogen-Activated Protein Kinase After Stimulation of Monocytes With Contact Sensitizers. J. Invest. Dermatol. 119: 99-106 (2002).
Bresinihan B., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12):2196-204(1998).
Burls and Jobanputra, The trials of anakinra, Lancet 364:827-828 (2004).
Butler, et al., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-10 (2003).
Cailleau et al., Treatment with neutralizing antibodies specific for IL-1 beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46:937-940 (1997).
Casadio, et al., Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1Beta/IL-1R1 complex. FEBS Letters 499:65-68 (2001).
Chen et al., Effects of interleukin-1 alpha, interleukin-1 receptor antagonist, and neutralizing antibody on pro-inflammatory cytokine expression by human squamous cell carcinoma lines Cancer Res. 58:3668-3676 (1998).
Chen, et al., My D88 dependent IL-1 receptor signalling is essential for gouty inflammation stimulated by monosodium urate crystals, J. Clin. Investig. 116(8): 2262-71 (2006).
Choi HK., et al., Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. (350):1093-1103 (2004).
Christodoulides, et al., Interaction of primary human endometrial cells with Neisseria gonorrhoeae expressing D green fluorescent protein. Mol. Microbiol 35 (1): 32-43 (2002).
Cronstein, et al., The Inflammatory Process of Gout and its Treatment, Arthritis Research & Therapy 8(Supp1): S3 (2006).
Darling, et al., Kinetic Exclusion Assay Technology: Characterization of Molecular Interactions. Assay and Drug Dev. Tech. 2(6): 647-657 (2004).
Dayer, The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 42 (Supp1.2):ii3-ii10 (2003).
D'Ettorre et al., Functional epitope mapping of human interleukin-113 by surface plasmon resonance. Eur. Cytokine Netw. 8:161-171 (1997).
Dezzutii, et al., Involvement of Matrix Metalloproteinases in Human Immunodeficiency Virus Type 1-Induced Replication by Clinical Mycobacterium avium Isolates. J.Infect. Dis. 180: 1142-520 (1999).
Di Giovine, et al., Interleukin 1 (IL-1) as a mediator of crystal arthritis, J. Immunology 138(10): 3213-3218 (1987).
Di Giovine, et al., Urate Crystals Stimulate Production of Tumor Necrosis Factor Alpha from Human Blood Monocytes and Synovial Cells, J. Clin. Invest. 87:1375-1381 (1991).
Dinarello CA, Interleukin-1, inteleukin-1 receptors and interleukin-1 receptor antagonist. Intern Rev Immunol. 16:457-499 (1998).
Dinarello et al., The production of antibody against human leukocytic pyrogen. J. Clin. Invest. 60:465-472 (1977).
Dinarello et al., Human leukocytic pyrogen: purification
Chen Gang
Haak-Frendscho Mary
Horwitz Arnold H.
Masat Linda
Roell Marina
K&L Gates LLP
Mertz Prema
Polo John
Xoma Technology Ltd.
LandOfFree
Method of treating an IL-1 related autoimmune disease or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating an IL-1 related autoimmune disease or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating an IL-1 related autoimmune disease or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162459